Bone Health

Immunology

Hematology

Respiratory

Dermatology

Diabetes

Gastroenterology

Neurology

Oncology

Ophthalmology

Rare Disease

Rheumatology

News

All News

Product Approvals and Launches

Media

All Videos

Insights

Interviews

Peer Exchange

Podcasts

Stakeholder Summit

Compendia

Conferences

Conference Coverage

Conference Listing

CME/CE

Resources

Authors

Biosimilar Resources

Interactive Tools

Partners

Polls and Quizzes

WHEN CHOICE ARRIVES: Competition & Consequences

Subscribe

BIOSIMILAR APPROVALS

Articles

Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption is hindered by misconceptions, regulatory gaps, and weak pharmacovigilance, requiring targeted education and stronger regulations.

Boosting Health Care Sustainability: The Role of Biosimilars in Latin America

Although financial incentives introduced by Japan's 2022 health policy did not result in a reduction in overall drug costs, biosimilar use in oncology significantly increased.

Financial Incentives Boost Oncology Biosimilar Adoption, but Costs Remain Unchanged 

The European Commission grants marketing authorization to 2 aflibercept biosimilars; Biosimilars Canada launches new campaign to provide sustainable solutions to employers; Celltrion shares positive data for 2 biosimilars.

Eye on Pharma: EU Aflibercept Approvals; Biosimilars Canada Campaign; Celltrion Data 

Sarfaraz K. Niazi, PhD, is an adjunct professor of biopharmaceutical sciences at the University of Illinois and the University of Houston, and founder of biosimilars companies Karyo Biologics and Adello Biologics. He also founded the biosimilar advisory company PharmSci.

BioRationality: A Proposal to Create a New Association With Rational Scientific Agenda

About

Editorial

Contact

Advisory Board

Do Not Sell My Information

Terms & Conditions

Privacy Policy

Center for Biosimilars®

Facebook

Twitter

LinkedIn

Business Practice

Business

Development

Legal

Policy

Practice

Regulatory

1rem

Experts discuss the transition from biologics to biosimilars and emphasize the importance of adaptability when non-medical switching occurs.

Opportunities for Biosimilars: A Multidisciplinary Perspective

Videos

Experts explore current and future use of biosimilars in dermatology, gastroenterology, and rheumatology.

Utilizing Recently Approved Biosimilars in Clinical Practice

Panelists explore opportunities for biosimilars to manage inflammatory conditions. 

Transitioning to Biosimilars: Considerations for Providers and Payers 

Clinical and social challenges associated with biosimilars are discussed by key opinion leaders.

Navigating Challenges Associated with Biosimilars Across Various Disease States

Providers speak to the importance of being knowledgeable of efficacy and safety data before prescribing biosimilars to patients.  

Provider Acceptance Driving Confidence in Biosimilar Therapy

Experts compare approaches to prescribing biosimilars over reference drugs.  

Decision-Making Process Surrounding Biosimilar Implementation

Panelists discuss reference biologic and biosimilar concentrations as well as the importance of citrate-free, less frequent injectable medications. 

Biosimilar Administration Considerations Impacting Patient Experience 

Vibeke Strand, MD, evaluates implementation of biosimilars in patients with no history of reference biologic use. 

Initiating Biosimilar Treatment in Patients Without Previous Reference Biologic Experience

Insight surrounding the switch from reference drugs to biosimilars is provided by Bincy Abraham, MD, MS.

Switching Patients from Reference Product to Biosimilar

Medical experts discuss interchangeability designation requirements for biosimilars.

Defining Interchangeability and Switching in Biologics

Professionals speak to auto-substitution and its Impact on the shared decision-making process associated with biosimilars.

Evolution of Auto-Substitution in Biosimilar Landscape 